Delivery of Xenon Polariser

RNS Number : 7473C

Polarean Imaging PLC

03 October 2018

 

Polarean Imaging Plc

("Polarean" or the "Company")

Delivery of Xenon Polariser

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces the delivery of the latest model of Polarean's Xenon polariser to The Department of Radiology at University of Missouri Health Care ("MUHC").

The Department of Radiology at MUHC is launching its research programme in pulmonary imaging and will use Polarean's hyperpolarised xenon technology as part of the programme.

Richard Hullihen, CEO of Polarean, said: "We are excited to deliver the newest version of our polariser to MUHC. We are grateful to Dr Altes, MUHC, and all the skilled researchers there, for the opportunity to work together and continue our research into the clinical applications of this emerging and much needed technology."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

Polarean Imaging plc		www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer			Via Walbrook PR
Richard Morgan, Chairman
Northland Capital Partners Limited			Tel: [phone]
David Hignell / Gerry Beaney / Jamie Spotswood (Corporate Finance) Rob Rees (Corporate Broking)
MC Services (European IR)			Tel: [phone]
Raimund Gabriel
The Life Sciences Division (Financial Adviser)
Navid Malik, Director			Mob: [phone]
Alia Minhas, CEO			Mob: [phone]
Walbrook PR	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy Helen Cresswell	Mob: [phone] [phone]

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

 

END

 

 

MSCGMMGGKZRGRZM